Research programme: monoclonal T-cell receptors based therapeutics - Immunocore

Drug Profile

Research programme: monoclonal T-cell receptors based therapeutics - Immunocore

Alternative Names: HCV-ImmTAC; Her2-ImmTAC; HIV-ImmTAC; IMC C103C; IMC D104C; IMC F106C; IMC-mage1; ImmTAB; ImmTACs; ImmTAV; Islet cell-ImmTAC; MAGE-A3-ImmTAC

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunocore
  • Class Anti-infectives; Antineoplastics; Antituberculars; Monoclonal antibodies; Proteins
  • Mechanism of Action Cytokine modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Hepatitis C; HIV infections; Tuberculosis
  • Research Autoimmune disorders
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 05 Sep 2018 Immunocore has patent protection for ImmTAC platform in Europe and China
  • 05 Sep 2018 Immunocore receives patent allowance for ImmTAC platform in USA
  • 03 May 2018 Immunocore plans a phase I/II trial for Cancer (Late-stage disease) in May 2018 , (NCT03515551)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top